Thymalin
Thymulin, Thymic Factor, Serum Thymic Factor, Facteur Thymique Serique
Unknown
PHASE2
INTERVENTIONAL
NCT05407649
Abscopal Effect of Radiotherapy in Combination With rhGM-CSF for Advanced Thymic Epithelial Tumours
View on ClinicalTrials.gov
Updated Dec 15, 2025
Brief Summary
The purpose of this study is to determine whether radiotherapy (RT) combined with recombined human granulocyte-macrophage colony stimulating factor(rhGM-CSF) is safe, effective in the treatment of patients with advanced thymic epithelial tumours.
Interventions
Name:
Radiotherapy Combined with GM-CSF
Type:
RADIATION
Description:
Patients with stable or progressing metastatic thymic epithelial tumours, with at least two distinct measurable sites of disease, were treated with concurrent radiotherapy (35 Gy in ten fractions or 60Gy in 30 fractions) to one metastatic site and granulocyte-macrophage colony-stimulating factor (125 μg/m(2) subcutaneously injected daily for 2 weeks, starting during the second week of radiotherapy).
Primary Outcomes
Measure:
The abscopal effect rate
TimeFrame:
up to 12 months
Description:
The proportion of patients with an abscopal response assessed after the initiation of treatment
The proportion of patients with an abscopal response assessed after the initiation of treatment
Trial Information
NCT ID
NCT05407649
Status
Unknown
Study Type
INTERVENTIONAL
Phases
PHASE2
Sponsor
Shanghai Cancer Hospital, China
Last Updated
December 15, 2025